Clinical Trial

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Name: FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma — clinical trial record (NCT04625907)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FaR-RMS

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2020-11-10; most recent amendment 2024-05-22.

Trial Details

NCT Number	NCT04625907
Lead Sponsor	University of Birmingham
Conditions	Rhabdomyosarcoma
Enrollment	1,672 participants
Start Date	2020-09-17
Primary Completion	2030-06 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2024-05-23